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Abstract 
Background. Vitamin K antagonists (VKA) have a narrow therapeutic range, and literature analysis reveals poor 
quality of anticoagulation control. We sought to assess the prevalence of poor anticoagulant control in patients under 
VKA treatment in the prevention of stroke for atrial fibrillation (AF). 
Hypothesis.Control of anticoagulation with VKA is inadequate in a high percentage of patients with AF. 
Methods.Patients with AF under VKA treatment were prospectively recruited in this observational registry. The 
sample comprised 948 patients. The estimated time spent in the therapeutic range (TTR) was calculated, and 
variables related with a TTR >65% were analyzed. 
Results.Mean age was 73.8 ± 9.4 years, and 42.5% of the patients were women. Mean TTR was 63.77% ± 23.80% for 
the direct method and 60.27% ± 24.48% for the Rosendaal method. Prevalence of poor anticoagulation control was 
54%. Variables associated with good anticoagulation control were university studies (odds ratio [OR]: 1.99, 95% 
confidence interval [CI]: 1.08-3.64), chronic hepatic disease (OR: 8.15, 95% CI: 1.57-42.24), low comorbidity 
expressed as Charlson index (OR: 0.87, 95% CI: 0.76-0.99), no previous cardiac disease (OR: 0.64, 95% CI: 0.41-
0.98), lower risk of bleeding assessed as hypertension, abnormal renal/liver function, stroke, bleeding history or 
predisposition, labile international normalized ratio, elderly age, and use of drugs or alcohol (HAS-BLED; OR: 0.81, 
95% CI: 0.69-0.95), and lower heart rate (OR: 0.99, 95% CI: 0.98-0.99). 
Conclusions.Patients who receive VKA to prevent stroke for AF spend less than half the time within therapeutic 
range. 
Introduction 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and the major indication for 
long-term oral anticoagulation worldwide.[1] Vitamin K antagonists (VKAs), although no longer the only 
option, remain the pharmaceutical group more widely employed, due to their relatively low price and 
large amount of experience. 
Coagulation status with VKAs needs to be monitored carefully to ensure maximal efficacy with 
minimal complication rates. The international normalized ratio (INR) is used to express the coagulation 
state, and several formulas have been proposed to assess the quality of anticoagulation. Among those 
formulas, the time in the therapeutic range (TTR) is the more extended and has proven to be a major 
determinant of the efficacy and safety of anticoagulation with VKAs.[2] 
Literature analysis reveals poor quality of anticoagulation control with VKAs,[3-6] but it also shows 
important differences among countries.[2] In patients with suboptimal anticoagulation control with 
VKAs, strategies aimed to improve this control must be undertaken, including switching to a non–vitamin 
K antagonist oral anticoagulant (NOAC). 
With this study we sought to assess the prevalence of poor anticoagulant control in patients under 
VKA treatment in the prevention of stroke for AF. 
  
Methods 
Patients 
FANTASIIA is a multicenter observational study. Cardiologists, general practitioners, and internists 
participated in the study recruiting 20 consecutive patients with nonvalvular AF receiving uninterrupted 
anticoagulant treatment for stroke prevention for >6 months. By design, 16 patients had to receive VKAs 
and 4 NOACs. Patients were excluded for age <18 years, history of heart valve disorder (including 
prosthesis or moderate/severe valve disease), hospitalization at the moment, or if they were participating 
in a clinical trial. Patients unwilling or unable to provide written informed consent were also excluded. 
The study was conducted in Spain. The research protocol complied with the Declaration of Helsinki and 
was approved by the local ethics committee. 
A total of 1290 patients were recruited; of those, 994 received VKAs (77.1%) and 296 received 
NOACs (22.9%). After the exclusion of 48 patients with incomplete registry of INR controls, the final 
sample for the analysis of quality of anticoagulation with VKAs consisted of 948 patients. 
Coagulation status was determined by INR values of the 6 months previous to the study entry. The 
INR values were registered together with other clinical and analytical variables. Chronic kidney disease 
was defined as estimated glomerular filtration rate <60 mL/min/1.73 m2, and chronic hepatic disease was 
defined as having a past medical history of cirrhosis, hepatitis, any other chronic liver disorder, or 
persistent elevation of transaminases 3× the upper limit of normal. Stroke and hemorrhagic risks were 
calculated by means of the CHA2DS2-VASc[7] and hypertension, abnormal renal/liver function, stroke, 
bleeding history or predisposition, labile INR, elderly age, and use of drugs or alcohol (HAS-BLED) 
scores,[8] and the presence of comorbid diseases was assessed with the Charlson index.[9] 
Quality of Anticoagulation 
International normalized ratio was determined monthly in the 6 months previous to the study entry. Direct 
method shows the proportion of INR controls within 2 and 3. The Rosendaal method uses linear 
interpolation to assign an INR value to each day between successive observed INR values.[10] The 
estimated time spent in the TTR was assessed by the Rosendaal method. Poor anticoagulation control was 
defined as an estimated TTR <65%.[11] 
Statistical Analysis 
All continuous variables showed normal distribution and are presented as mean ± SD. Discrete variables 
are presented as values (percentages). Baseline characteristics were compared between patients with 
adequate (TTR ≥65%) or inadequate (TTR <65%) VKA control. Logistic regression analyses were 
employed for univariate analyses and for multivariate adjustment. Multivariate models were performed 
including variables with recognized clinical relevance with VKA control and those with a P value <0.1 in 
the univariate analysis. Results are presented as odds ratios (ORs) and 95% confidence intervals (95% 
CIs). A 2-sided P value of <0.05 was considered to be significant for all analyses. All statistical analyses 
were performed using SPSS version 13.0 (SPSS Inc., Chicago, IL). 
Results 
Mean age of the study population was 73.8 ± 9.4 years, and 42.5% of the patients were women. Clinical 
characteristics of the sample are depicted in Table 1. 
Unadjusted analyses (Table 2) revealed higher control rates for higher education level; absence of 
cardiovascular risk factors: hypertension (78.52% TTR ≥65% vs 83.69% TTR <65%; OR: 0.71, P = 
0.04), diabetes mellitus (27.25% TTR ≥65% vs 34.37% TTR <65%; OR: 0.72, P = 0.02), less 
comorbidity expressed as lower mean Charlson index (1.09 TTR ≥65% vs 1.30 TTR <65%; OR: 0.86, P 
= 0.01), lower thrombotic risk (CHADS2: 2.22 TTR ≥65% vs 2.40 TTR <65%; OR: 0.89, P = 0.02) and 
hemorrhagic risk (HAS-BLED: 1.90 TTR ≥65% vs 2.08 TTR <65%; OR: 0.85, P = 0.01), and better 
glycemic control (glycemia: 107.05 TTR ≥65% vs 112.8 TTR <65%; OR: 0.99, P = 0.01, and glycated 
hemoglobin 6.10 TTR ≥65% vs 6.35 TTR <65%; OR: 0.86, P = 0.02). (For detailed pharmacological 
treatment, see Supporting Table in the online version of this article.)
Table 1. Baseline Characteristics of the Study Population Stratified by Time in the TTR 
Variable Total (N = 948) TTR <65% (n = 515) TTR ≥65% (n = 433) P Value 
     
Age, y 74.01 73.75 74.33 0.34 
Female sex 43.25 42.33 44.34 0.53 
Education     
Cannot write (Ref) 5.8 6.99 4.39  
Primary 70.15 71.26 68.82 0.14 
Secondary 15.30 15.34 15.24 0.16 
Higher education 3.06 2.52 3.70 0.07 
University degree 5.70 3.88 7.85 0.00 
HTN 81.33 83.69 78.52 0.04 
Hyperlipidemia 54.85 53.40 56.58 0.33 
DM 31.12 34.37 27.25 0.02 
Smoking history     
Nonsmoker (Ref) 62.03 61.36 62.82  
Current smoker 4.43 5.63 3.00 0.06 
Recent former smoker (<1 year) 2.22 2.33 2.08 0.76 
Former smoker (<1 year) 31.33 30.68 32.10 0.88 
Chronic pulmonary disease 16.67 17.09 16.17 0.70 
Chronic kidney disease 21.10 22.52 19.40 0.24 
Chronic hepatic disease 1.16 0.58 1.85 0.09 
Active cancer 9.28 10.49 7.85 0.17 
PAD 6.96 7.77 6.00 0.29 
CVD     
None (Ref) 85.02 84.85 85.22  
Ischemic 9.92 9.51 10.39 0.70 
Transient ischemic 4.32 4.85 3.70 0.40 
Hemorrhagic 0.74 0.78 0.69 0.88 
Systemic embolism 2.22 2.52 1.85 0.48 
Charlson index 1.20 1.30 1.09 0.01 
HF 31.75 34.37 28.64 0.06 
CAD 20.25 20.78 19.63 0.66 
DCM 13.29 13.20 13.39 0.93 
Hypertrophic cardiomyopathy 3.06 3.11 3.00 0.93 
LVH 17.19 16.70 17.78 0.66 
Recent bleeding (6 months) 2.53 3.30 1.62 0.11 
Type of AF     
Paroxysmal (Ref) 26.9 26.80 27.02  
Persistent 17.72 18.25 17.09 0.71 
Long-term persistent 3.90 3.69 4.16 0.75 
Permanent 51.48 51.26 51.73 1.00 
EHRA functional class     
I (Ref) 38.61 40.39 36.49  
II 52.32 49.71 55.43 0.13 
III 8.65 9.51 7.62 0.63 
IV 0.42 0.39 0.46 0.78 
CHADS2 score, mean 2.32 2.40 2.22 0.02 
CHA2DS2-VASc score, mean 3.79 3.87 3.70 0.10 
HAS-BLED score, mean 1.99 2.08 1.90 0.01 
Rhythm at inclusion     
Sinus (Ref) 30.80 28.54 33.49  
AF 61.81 63.30 60.05 0.14 
Pacemaker 6.54 7.18 5.77 0.18 
Other 0.84 0.97 0.69 0.50 
Conduction disturbances     
None (Ref) 77.34 80.59 73.47  
AV block 3.54 4.36 2.58 0.25 
RBBB 10.31 7.52 13.62 0.00 
LBBB 8.81 7.52 10.33 0.08 
LVEF, %, mean 58.29 58.09 58.53 0.59 
Hg, g/dL, mean 13.66 13.69 13.63 0.64 
sCr, mg/dL, mean 1.07 1.09 1.06 0.33 
eGFR, mL/min/1.73 m2, mean 65.49 65.75 65.17 0.70 
Glycemia, mg/dL, mean 110.18 112.81 107.05 0.01 
HbA1c, %, mean 6.23 6.35 6.10 0.02 
     
 
Abbreviations: AF, atrial fibrillation; AV block, atrioventricular block; CAD, coronary artery disease; CI, confidence interval; 
CVD, cerebrovascular disease; DCM, dilated cardiomyopathy; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; 
EHRA, European Heart Rhythm Association; HbA1c, glycated hemoglobin; HF, heart failure; Hg, hemoglobin; HTN, hypertension; 
LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; RBBB, right bundle 
branch block; Ref, reference category; PAD, peripheral artery disease; sCr, serum creatinine; TTR, time in the therapeutic range. 
Data are presented as % unless otherwise indicated.
Table 1. Univariate Comparison of the Population With Effect of Each Variable on the Quality of Anticoagulation 
Variable TTR < 65% (n = 515) TTR ≥65%(n = 433) OR 95% CI P Value 
      
Age, y 73.75 74.33 1.01 0.99-1.02 0.34 
Female sex 42.33 44.34 1.09 0.84-1.40 0.53 
Education      
Cannot write (Ref) 6.99 4.39    
Primary 71.26 68.82 1.54 0.86-2.74 0.14 
Secondary 15.34 15.24 1.58 0.83-3.02 0.16 
Higher education 2.52 3.70 2.33 0.93-5.85 0.07 
University degree 3.88 7.85 3.22 1.47-7.05 0.00 
HTN 83.69 78.52 0.71 0.51-0.99 0.04 
Hyperlipidemia 53.40 56.58 1.14 0.88-1.47 0.33 
DM 34.37 27.25 0.72 0.54-0.95 0.02 
Smoking history      
Nonsmoker (Ref) 61.36 62.82    
Current smoker 5.63 3.00 0.52 0.27-1.02 0.06 
Recent former smoker (<1 year) 2.33 2.08 0.87 0.36-2.10 0.76 
Former smoker (<1 year) 30.68 32.10 1.02 0.77-1.35 0.88 
Chronic pulmonary disease 17.09 16.17 0.94 0.66-1.32 0.70 
Chronic kidney disease 22.52 19.40 0.83 0.60-1.13 0.24 
Chronic hepatic disease 0.58 1.85 3.21 0.85-12.19 0.09 
Active cancer 10.49 7.85 0.73 0.46-1.14 0.17 
PAD 7.77 6.00 0.76 0.45-1.26 0.29 
CVD      
None (Ref) 84.85 85.22    
Ischemic 9.51 10.39 1.09 0.71-1.67 0.70 
Transient ischemic 4.85 3.70 0.76 0.40-1.44 0.40 
Hemorrhagic 0.78 0.69 0.89 0.20-3.99 0.88 
Systemic embolism 2.52 1.85 0.73 0.30-1.77 0.48 
Charlson index 1.30 1.09 0.86 0.77-0.96 0.01 
HF 34.37 28.64 0.77 0.58-1.01 0.06 
CAD 20.78 19.63 0.93 0.68-1.28 0.66 
DCM 13.20 13.39 1.02 0.70-1.48 0.93 
Hypertrophic cardiomyopathy 3.11 3.00 0.97 0.46-2.03 0.93 
LVH 16.70 17.78 1.08 0.77-1.51 0.66 
Recent bleeding (6 months) 3.30 1.62 0.48 0.20-1.17 0.11 
Type of AF      
Paroxysmal (Ref) 26.80 27.02    
Persistent 18.25 17.09 0.93 0.63-1.37 0.71 
Long-term persistent 3.69 4.16 1.12 0.56-2.23 0.75 
Permanent 51.26 51.73 1.00 0.74-1.36 1.00 
EHRA functional class      
I (Ref) 40.39 36.49    
II 49.71 55.43 1.23 0.94-1.62 0.13 
III 9.51 7.62 0.89 0.54-1.44 0.63 
IV 0.39 0.46 1.32 0.18-9.45 0.78 
CHADS2 score, mean 2.40 2.22 0.89 0.80-0.98 0.02 
CHA2DS2-VASc score, mean 3.87 3.70 0.93 0.86-1.01 0.10 
HAS-BLED score, mean 2.08 1.90 0.85 0.75-0.96 0.01 
Rhythm at inclusion      
Sinus (Ref) 28.54 33.49    
AF 63.30 60.05 0.81 0.61-1.07 0.14 
Pacemaker 7.18 5.77 0.68 0.39-1.20 0.18 
Other 0.97 0.69 0.61 0.14-2.59 0.50 
Conduction disturbances      
None (Ref) 80.59 73.47    
AV block 4.36 2.58 0.65 0.31-1.36 0.25 
RBBB 7.52 13.62 1.98 1.28-3.07 0.00 
LBBB 7.52 10.33 1.51 0.95-2.38 0.08 
LVEF, %, mean 58.09 58.53 1.00 0.99-1.02 0.59 
Hg, g/dL, mean 13.69 13.63 0.98 0.91-1.06 0.64 
sCr, mg/dL, mean 1.09 1.06 0.87 0.66-1.15 0.33 
eGFR, mL/min/1.73 m2, mean 65.75 65.17 1.00 0.99-1.00 0.70 
Glycemia, mg/dL, mean 112.81 107.05 0.99 0.99-1.00 0.01 
HbA1c, %, mean 6.35 6.10 0.86 0.76-0.98 0.02 
      
 
Abbreviations: AF, atrial fibrillation; AV block, atrioventricular block; CAD, coronary artery disease; CI, confidence interval; 
CVD, cerebrovascular disease; DCM, dilated cardiomyopathy; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; 
EHRA, European Heart Rhythm Association; HbA1c, glycated hemoglobin; HF, heart failure; Hg, hemoglobin; HTN, hypertension; 
LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; RBBB, right bundle 
branch block; Ref, reference category; PAD, peripheral artery disease; sCr, serum creatinine; TTR, time in the therapeutic range. 
An OR >1 indicates that the presence of the variable increases the likelihood of good anticoagulation control, assessed by TTR 
≥65%.
Prevalence of poor anticoagulation control was 54% (515 patients with TTR <65%). Mean TTR was 
63.77% ± 23.80% for the direct method and 60.27% ± 24.48% for the Rosendaal method. Each patient 
was 90.41 ± 36.72 days within the therapeutic range out of the 180 days of registry. A total of 4.7% of the 
study population was between 0 and 30 days within INR range 2–3; 17.3% between 30 and 60 days; 
26.4% between 60 and 90 days; 21% between 90 and 120 days; and 21% >120 days. None of the INR 
values were within range in 1.3% of the sample; 4.4% had only 1 determination within range; 12.1% had 
2; 22.9% had 3; 24.7% had 4; 21.7% had 5; and 13.5% of patients had all their INR measurements 
between 2 and 3. 
After multivariate adjustment (Table 3), variables associated with good anticoagulation control were 
university studies (OR: 1.99, 95% CI: 1.08-3.64), chronic hepatic disease (OR: 8.15, 95% CI: 1.57-
42.24), low comorbidity expressed as Charlson index (OR: 0.87, 95% CI: 0.76-0.99), no previous cardiac 
disease (OR: 0.64, 95% CI: 0.41-0.98), lower risk of bleeding assessed as HAS-BLED (OR: 0.81, 95% 
CI: 0.69-0.95), and lower heart rate (OR: 0.99, 95% CI: 0.98-0.99). 
Table 3. Multivariable Analysis, Variables Associated With TTR ≥65% 
Variable OR 95% CI P Value 
    
University studies 1.99 1.08-3.64 0.03 
Chronic hepatic disease 8.15 1.57-42.24 0.01 
Charlson index 0.87 0.76-0.99 0.03 
No previous cardiac disease 0.64 0.41-0.98 0.04 
HAS-BLED 0.81 0.69-0.95 0.01 
Heart rate (bpm) 0.99 0.98-1.00 0.03 
    
 
Abbreviations: CI, confidence interval; ECG, electrocardiogram; HAS-BLED, hypertension, abnormal renal/liver function, stroke, 
bleeding history or predisposition, labile INR, elderly age, and use of drugs or alcohol; INR, international normalized ratio; OR, 
odds ratio; TTR, time in the therapeutic range. 
Model adjusted by age, sex, kidney disease, ECG conduction disturbances, previous ablation, and diuretic treatment. 
Discussion 
Our study shows a rate of inadequate control with AVKs of 54%, and 46% of the patients spent more than 
half the time outside the therapeutic range. 
The poor control of anticoagulation is of concern. Prognosis of patients under anticoagulant treatment 
has been proven to differ significantly according to INR control,[3, 12, 13] and some strategies are now 
available to improve the quality of oral anticoagulation. Those strategies include the use of computer-
assisted dosing tools, self-monitoring, improving patient compliance, use of dedicated anticoagulation 
clinics, genotype-guided dosing, and switch to NOACs.[3, 14, 15] Causes of the low achievement of 
adequate anticoagulation are multiple, including underuse of strategies designed to improve control, 
therapeutic inertia, comorbidities, and socioeconomical variables that preclude the use of NOACs. Efforts 
have been made to increase the prescription of anticoagulation for patients with AF in accordance with 
international guidelines,[16, 17] but the quality of this anticoagulation has to be evaluated. 
A large observational study involving 6250 patients from France, Germany, Italy, and the United 
Kingdom treated with VKAs and with available INR has recently been published. Good VKA control was 
defined as TTR >70%; the rates of inadequate control found were 52% in France, 56% in Germany, 54% 
in Italy, and 45% in the United Kingdom.[18] A pooled analysis of AF studies published between 1990 
and 2013 showed a mean TTR of 61% and 56% of INR measures within therapeutic range,[2] whereas an 
older meta-analysis including studies performed in the United States showed a mean TTR of 57% and 
51% of time within range.[3] A more recent study showed TTR values between 70.3% and 81.4% among 
Western European countries.[19] 
In our study, the variables associated with adequate VKA adjustment were higher education, 
expressed as having a university degree; low comorbidity, expressed as low Charlson index; no previous 
cardiac disease, lower risk of bleeding, chronic hepatic disease, and lower heart rate. Classic studies 
evaluating compliance with anticoagulants revealed that younger age, male sex, or nonwhite race were 
factors associated with lack of compliance.[20] A more recent study revealed poor compliance with 
anticoagulants in patients with higher educational level, current employment, and lower scores on mental 
health or cognitive functioning.[21] This apparent controversy was explained by the decreased trust in 
physicians among more educated subjects, whereas poor cognition has been associated with worse 
treatment adherence also in other areas.[22] In our study, having a university degree was associated with 
adequate anticoagulation control. We believe that higher education helps patients to understand the 
importance of anticoagulant treatment adherence. The association we have found between education and 
control is not limited to university studies; on the contrary, we can see a progressive increase in the OR 
for adequate control for progressively higher levels of education (Table 2). 
The explanation of how chronic liver disease and lower heart rate are associated with adequate VKA 
control is unclear. We speculate that both patients and physicians are more careful when anticoagulating 
patients with chronic liver disease. Patients with higher heart rate are more prone to heart failure 
decompensation and to receive chronotropic/antiarrhythmic drugs, 2 factors that may interfere with VKA 
anticoagulation. These hypotheses need to be confirmed in future studies. 
Study Limitations 
We must acknowledge several study limitations. First, ours is an observational, transversal study. Second, 
we do not know which patients had their INR controls performed by general practitioners, cardiologists, 
hematologists, or anticoagulation clinics, or by self-monitoring. Duration of the arrhythmia and 
echocardiographic variables other than left ventricular ejection fraction were not available, and thus these 
data have not been analyzed. The results we present are representative of Spain, but previous reports have 
shown that in Spain INR control is equal or superior to that in other Western countries such as Italy, 
France, the United States, or Canada.[23] Another peculiarity of our study is that in Spain the 
predominant VKA is acenocoumarol, as opposed to most Western countries, where warfarin is mainly 
used. 
Conclussion 
Patients who receive VKAs to prevent stroke for AF spend <50% of the time within therapeutic range. 
Efforts must be made to improve efficacy and security of chronic anticoagulation. 
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